This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It further reported that these results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronaryarterydisease. “We He is the author of over 150 articles, book chapters, abstracts and other publications on advanced imaging technologies. 2023 Dec 12:jead339.
mtaschetta-millane Thu, 07/25/2024 - 08:55 July 25, 2024 — Nanox, an innovative medical imaging technology company, announced that the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox.AI was highlighted in multiple scientific presentations at the 2024 Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting. “We
In 2024, the FDA approved Flyrcado for patients with known or suspected coronaryarterydisease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today.
ObjectiveThis study focuses on the innovative application of Automated Machine Learning (AutoML) technology in cardiovascular medicine to construct an explainable CoronaryArteryDisease (CAD) prediction model to support the clinical diagnosis of CAD.MethodsThis study utilizes a combined data set of five public data sets related to CAD.
a pioneering medical technology company specializing in cardiovascular interventional devices, today announced that its groundbreaking Acolyte Image Guided Crossing and Re-Entry Catheter System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ).
Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. After implantation, the locked phase establishes the maximum flow lumen and restores blood flow to treat symptoms of coronaryarterydisease (CAD).
With the continuous progress of science and technology, artificial intelligence (AI) has become an important driving force for a new round of scientific and technological revolution and industrial change. In recent years, the attempts of AI to run through the whole process of CCTA have expanded the application scope of CCTA.
CLTI is the most severe form of peripheral arterialdisease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. degradation of magnesium observed 12 months after implantation in coronaryarteries.4 2,3 It has shown 99.6%
GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.
FDA Breakthrough Device Designation recognizes novel innovations that demonstrate the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. For more information: [link] References: 1 Maurer M, Elliott P, Comenzo R, et al.
milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its CoronaryArteryDisease ( CAD ) Staging System.
milla1cf Tue, 06/25/2024 - 18:58 June 25, 2024 — Nano-X Imaging (Nanox), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography ( SCCT (..)
6 Also in 2023, HeartFlow released its RoadMap Analysis which helps identify and quantify narrowings in the coronaryarteries and has demonstrated a 25% faster CCTA read time. HeartFlow is committed to serving customers quickly and reliably with a median turnaround time less than 1.5
Attendees can join with their peers and participate in sessions on structural heart disease, congenital heart disease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronaryarterydisease, vascular heart disease, debates and games and early career topics. for all attendees.
A prospective multi-center clinical study of the device is scheduled to begin enrollment this year. “We have many interventional or surgical revascularization options for patients with advanced large coronaryarterydisease. However, a significant proportion still suffer from angina. VahatiCor, Inc.,
This innovative approach integrates personal data from multiple biological layers to design bespoke dietary plans, transcending the limitations of one-size-fits-all recommendations. Accessibility: Addressing the cost and availability of advanced technologies to ensure widespread access to precision nutrition.
By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patient care. The latest technology utilizes the existing data of an Artificial Neural network (ANN). Novel technology is also proving to be better than traditional conventional ECG machines. For instance: 1.
Interventional cardiology has dramatically evolved over the past decades, introducing advanced techniques and tools that have revolutionized the treatment of coronaryarterydisease, valvular disorders, and structural heart diseases.
Interventional cardiology has dramatically evolved over the past decades, introducing advanced techniques and tools that have revolutionized the treatment of coronaryarterydisease, valvular disorders, and structural heart diseases.
These technologies are not just reshaping but also empowering how cardiology practices manage operations, deliver care, and enhance patient outcomes. These technologies are reshaping how cardiology practices manage operations, deliver care, and enhance patient outcomes.
Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.
v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronaryarterydisease (CAD), making it a valuable tool for clinicians.
Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. Cleerly’s pioneering approach to advanced cardiovascular imaging, powered by AI-driven analysis, is elevating the field of diagnostic tools for coronaryarterydisease.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronaryarterydisease (CAD) and peripheral arterydisease (PAD).
Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronaryarterydisease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. 101272, [link].
Image courtesy: Philips christine.book Wed, 06/12/2024 - 14:07 June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.
Improved patient safety with reduced radiation and contrast load Enhancing patient safety is a pivotal aspect of advanced cardiac imaging technology. By employing advanced scanning technology, healthcare providers can ensure patients undergo diagnostic procedures with minimized risks.
The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronaryarterydisease. The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions, according to a written statement on the designation.
Computed Tomography (CT) continues to be a rapidly evolving technology with many new advancements, as displayed and discussed at the Radiological Society of North America109th Scientific Assembly and Annual Meeting (RSNA23). As a whole, the computed tomography market size in the US in 2024 is estimated to be $2.38
Those who had ventricular fibrillation were more likely to be younger, have had coronaryarterydisease or experienced chest pain as a warning symptom. “We “We plan to continue to study this AI method to learn how it could be used in a clinical setting.”
The Role of Cardiologists Cardiologists are at the forefront of the battle against heart diseases. Their expertise covers a wide range of cardiovascular conditions, including coronaryarterydisease, heart failure, arrhythmias, and congenital heart defects.
Technology provides us with more and more possibilities in many areas of life, including medicine. It is no longer just a future dream, but a new reality for clinicians and patients who can already benefit from new technologies. Cardiovascular diseases are a group of diseases of the heart and blood vessels.
From breakthrough medications to innovativetechnologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Personalized Cardiometabolic Care TRANSFORM Program for CoronaryArteryDisease (CAD) : The TRANSFORM program focuses on atherosclerosis-based care strategies rather than traditional risk-based approaches.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
103 
Let's personalize your content